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ABSTRACT

Human pulmonary artery smooth muscle cells (HPASMC) maintain the vascular
tone and exhibit myogenic reactivity in the pulmonary arteries. The BKCa channel, being
the predominate K+ channel within the HPASMC, is important in regulating the
pulmonary arterial pressure and because the BKCa channel’s activity can be modulated by
various molecules, studies have evaluated the role that altered BKCa channel expression
and function plays in the dysfunction of the HPASMC during type 2 diabetes (T2D). The
results from those studies provided a basis for this project. In this study, cell cultures,
western blot experiments, and cAMP assays were employed to evaluate the BKCa channel
expression and function in HPASMC from a non-diabetic individual (NHPASMC) and
HPASMC from a type 2 diabetic individual (D2HPASMC). In the western blot results,
there was altered expression of the BKCa channel α- and β1-subunits in the D2HPASMC.
In the cAMP assay results, following exposure to a known adenylate cyclase activator,
cAMP levels were increased in the NHPASMC and D2HPASMC, but the D2HPASMC
exhibited overall lower cAMP levels. These alterations to the BKCa channel’s expression
and function provide further support that impaired BKCa channel function may contribute
to dysfunction of the vascular smooth muscle in the pulmonary arteries that may then
lead to the development of pulmonary hypertension.
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Introduction
1.1 Diabetes Mellitus
As more people are diagnosed with diabetes, its systemic effect on the vasculature
and its effect on the management of other disease states has become an interest of several
studies. According to the World Health Organization (WHO), more than 95% of people
living with diabetes have type 2 diabetes (Diabetes. 2021). Type 2 diabetes (T2D) is a
metabolic disorder in which the body’s ability to regulate its blood glucose levels is
impaired due to an inability to use insulin properly. Insulin is a polypeptide hormone that
is produced and secreted from the β-cells in the islets of Langerhans of the pancreas
(Rahman et al., 2021). Insulin functions to regulate the body’s energy supply by
stimulating cells to uptake glucose whenever there is a high blood glucose concentration.
A group of transmembrane glucose transporter proteins (GLUT) mediates the insulinstimulated glucose transport across cell membranes. The majority of insulin-stimulated
glucose uptake occurs in skeletal muscle via GLUT4 which is the glucose transporter
protein that specifically mediates the transport of glucose into skeletal muscle, cardiac
muscle, and adipose tissue.
Under basal/fasting conditions where there are low blood glucose levels, GLUT4
is sequestered intracellularly and slowly cycles between the cell membrane and
intracellular GLUT4 storage vesicles (GSVs), but the majority of the GLUT4 proteins are
located within the interior of the cell. The insulin receptor (IR) expressed on the surface
of insulin-responsive cells is composed of 2 extracellular α-subunits bound via disulfide
bonds to 2 transmembrane β-subunits. With high blood glucose levels, insulin is released
from the pancreatic β-cells and binds to the α-subunits of the IR causing a conformational
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change to occur that activates tyrosine kinases in the β-subunits leading to the
phosphorylation of tyrosine at several intracellular sites (Watson & Pessin, 2001). These
tyrosine phosphorylation sites are contained within the insulin receptor substrate protein
(IRS-1) and other substrates, which act as docking sites for effector proteins.
While it is believed that several proteins are involved in the insulin signal
transduction process, studies have shown that in order to have rapid translocation of
GLUT4 to the cell membrane it is necessary to have the activation of
phosphatidylinositol 3-kinase (PI3K) and Akt. PI3K is activated through an association
with the substrates of the IR, and this leads to the phosphorylation of several proteins
then the eventual phosphorylation of Akt that catalyzes the phosphorylation of the AS160
substrate that stimulates the translocation of GLUT4 to the cell membrane (Świderska et
al., 2018). While this pathway is necessary for GLUT4 translocation, studies also suggest
that there is at least one additional pathway in the insulin signaling process that functions
independent of the PI3K pathway. This process of insulin signaling leads to an increase
in GLUT4 exocytosis and a decrease in the endocytosis of GLUT4 (Watson & Pessin,
2001). Normal insulin signaling allows insulin-sensitive tissues to respond rapidly to
insulin in order to supply an abundance of GLUT4 proteins on the cell membrane
allowing for the transport of glucose into cells for storage or metabolism (Maier &
Gould, 2000).
In the early stages of the development of T2D, there is the failure of GLUT4 to
translocate to the cell membrane from GSVs. It is believed that this is due to an inability
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of insulin to signal for the movement of GLUT4 from the intracellular stores to the cell
surface resulting in a decreased cellular response to insulin that leads to hyperglycemia
(Maier & Gould, 2000). Hyperglycemia is categorized as a blood glucose level greater
than 125 mg/dL while fasting or greater than 180 mg/dL 2 hours postprandial (Mouri &
Badireddy, 2022). The decreased insulin sensitivity observed in T2D differs from the
dysfunction seen in type 1 diabetes (T1D) which is characterized as an autoimmune
disease where there is a destruction in the pancreatic β-cells resulting in a decrease in the
production of insulin.
While there is a decrease in pancreatic β-cell mass in both T1D and T2D, how this
decline occurs differs between the two. In T1D, there is an autoimmune mediated
decrease in β-cell mass and there is a decrease in β-cell function which both contribute to
the insulin deficiency observed in T1D individuals. The autoimmune attack of the β-cells
during T1D is caused by CD4+ and CD8+ T-cell-mediated destruction, but how exactly
this immune response contributes to the pathogenesis of T1D in humans is still unclear
(Pathiraja et al., 2014). In the Non-Obese Diabetic (NOD) mouse model, T-cell responses
against the insulin precursor, pro-insulin, have been identified in the development of
T1D. Because this relationship indicates that proinsulin acts as an autoantigen during
T1D, studies have been done to detect proinsulin-specific CD4+ T-cell responses in
peripheral blood mononuclear cells from both T1D and nondiabetic individuals, but
researchers have not been able to analyze the CD4+ T-cells in depth (Pathiraja et al.,
2014). Additionally, current studies have been unable to determine whether the decrease
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in β-cell function is due to the loss in β-cell mass or if the loss in β-cell function occurs
independently, but it is believed that these two processes do not occur completely
independent of one another (Matveyenko & Butler, 2008).
Studies suggest that the onset of T2D is also marked by a decrease in β-cell mass.
Autopsies done on individuals with T2D from various populations show a significant
reduction in the number of β-cells in comparison to the autopsies done on non-diabetic
individuals, with a range in decrease of β-cells in T2D individuals being from ~20% to
~65% (Meier & Bonadonna, 2013). Studies have been unable to identify a singular cause
of the decline in β-cell mass, but results from western blot analysis suggest that an
increase in β-cell apoptosis leads to the decline. The cause of the β-cell apoptosis is
unclear, but there have been a few mechanisms thought to contribute like high
concentrations of glucose or free fatty acids, a generation of reactive oxygen species
(ROS) because of a high secretory demand due to hyperglycemia, and the production of
inflammatory signals within the β-cells (Meier & Bonadonna, 2013). These results
suggest that though a decline in β-cell mass occurs in both T1D and T2D, the
mechanisms that causes the decline differs requiring different treatments needed to
address the dysfunction that occurs in T1D and T2D individuals.
1.1.1 Type 2 Diabetes Symptoms and Diagnosis
Some of the most common symptoms of T2D include frequent urination,
increased thirst, fatigue, and numbness or tingling in the hands and/or feet (Type 2
Diabetes | NIDDK. ). Some common methods used to diagnose T2D are a fasting plasma
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glucose test, which measures the blood glucose levels at that present time, or an A1c test,
which gives an average of the blood glucose levels over the past 3 months (Diabetes
Tests & Diagnosis | NIDDK. ). A diagnosis of T2D is characterized by a fasting plasma
glucose level of 126 mg/dL or higher or an A1c level of 6.5% or higher (Mouri &
Badireddy, 2022). Individuals diagnosed with T2D can often control their blood glucose
levels through adjusting their diet and exercising more, but others have to use
medications to manage their T2D. Though there are effective ways to diagnose T2D,
some people may be asymptomatic and can go without diagnosis and treatment for years.
Additionally, some people diagnosed with T2D may not be able to consistently regulate
their blood glucose levels and some may go for extended periods of time without
treatment.
1.1.2 Type 2 Diabetes Treatment
Different treatments are available for T2D to delay disease progression and
prevent the development of any diabetic complications, but there are several factors that
influence which treatments best suits each individual. There may not be a need for any
medications if blood glucose levels can be regulated through adjusting one’s diet or
increasing physical activity. If these methods are not enough to regulate blood glucose
levels, medications can be added to one’s treatment plan, but before considering any
medications, factors like the individual’s age, if they have any other medical conditions,
and whether or not they are taking any other medications must first be considered
(Information, National Center for Biotechnology et al., 2020). There are various types of
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medications, known as anti-diabetic medications, that can be used to lower blood glucose
levels, but their use must be regulated because some of these medications can also cause
blood glucose levels to decrease too much causing hypoglycemia.
A common anti-diabetic medication that has been well studied and has been
reported as well tolerated among T2D individuals is Metformin. It works by reducing
hepatic gluconeogenesis and the intestinal absorption of glucose and it also increases
peripheral glucose uptake and utilization to improve insulin sensitivity (Li et al., 2018).
When taken alone, Metformin rarely causes hypoglycemia because it does not act on the
pancreas to affect insulin production, therefore it is usually recommended first as an antidiabetic medication (Schernthaner & Schernthaner, 2020). Though an effective antidiabetic medication, Metformin poses contraindications in individuals with impaired
kidney function, liver disease, a history of lactic acidosis with metformin therapy, or
acute heart failure (Contraindications to Metformin Therapy.1998).
Sulfonylureas are another type of drugs that are often used to treat T2D, and they
work by stimulating the secretion of insulin from the pancreas by closing ATP-sensitive
K+ channels on the β-cell membrane which causes a cascade of events leading to the
release of insulin (Ashcroft, 1996). Sulfonylureas are often used in T2D individuals that
are not overweight or for those whom Metformin either does not efficiently provide
glycemic control or is contraindicated (Sola et al., 2015). Due to their mechanism of
action, Sulfonylureas may cause hypoglycemia, which is often due to excessive dosage,
and they may also cause weight gain when beginning treatment. Though typically well
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tolerated, some T2D individuals may experience allergic reactions to sulfonylureas (Sola
et al., 2015).
Glinides are a group of drugs that can be used to treat T2D through increasing the
production of insulin in the body. Glinides have a similar mechanism of action to
sulfonylureas by causing the release of insulin from the β-cells of the pancreas through
inhibiting ATP-sensitive K+ channels in order to control postprandial hyperglycemia
(Guardado-Mendoza et al., 2013). These drugs are short acting but may be optimal for
individuals with allergies to sulfonylureas. Less weight gain and lower incidences of
hypoglycemia have been reported compared to sulfonylureas, but in comparison to
Metformin, glinides may cause more instances of hypoglycemia (Information, National
Center for Biotechnology et al., 2020).
Gliptins are dipeptidyl peptidase-4 inhibitors (DPP-4s) that are used to treat T2D
through altering insulin secretion. Unlike sulfonylureas and glinides, these drugs not only
increase insulin secretion from the β-cells following an increase in blood glucose levels,
but they also work to decrease the secretion of glucagon from the α-cells of the pancreas
which decreases the release of hepatic glucose (Bohannon, 2009). Gliptins inhibit the
breakdown of glucagon-like peptide-1 (GLP-1) resulting in the signaling for insulin
secretion and suppressed glucagon secretion following a meal. Gliptins work to improve
insulin secretion in response to an increase in blood glucose levels, which differs from
the mechanism of action of Metformin, so several studies have shown when gliptins are
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taken alone or in conjunction with Metformin there is improved β-cell function and
improved glycemic control (Bohannon, 2009).
The development of T2D is marked by an initial insulin resistance due to a
decrease in response to insulin by several tissues which eventually leads to
hyperglycemia. Glitazones work by specifically targeting insulin resistance through
increasing the liver and skeletal muscle’s sensitivity to insulin resulting in an increase in
their uptake of glucose (Daniel, 2000). Though the mechanism of action of these drugs
offers a different target than other anti-diabetic medications, these drugs have shown
several side effects, including heart failure and an increased risk of bladder cancer, so
these drugs are not the first drug of choice used to treat T2D (Information, National
Center for Biotechnology et al., 2020). Gliflozins are a class of drugs that inhibit the
sodium glucose cotransporter type 2 (SGLT2) proteins in the proximal renal tubule
causing an increase in glucose excretion that lowers blood glucose levels, but these drugs
have been shown to increase the risk of acidosis (Information, National Center for
Biotechnology et al., 2020; Katharina Seoudy et al., 2021).
In rare cases, treatment with an anti-diabetic medication is not enough to lower
blood glucose levels, so some T2D individuals may need insulin therapy. Studies have
looked into whether there is a need for insulin use opposed to using a combination of
anti-diabetic medications whenever a single anti-diabetic medication does not adequately
control blood glucose levels. Results suggest that insulin was better at lowering blood
glucose levels, but there were no differences between insulin therapy and a combination
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of anti-diabetic medications in the long-term effect of diabetes leading to diabetic
complications (Information, National Center for Biotechnology et al., 2020).
Overall, management of T2D must be done through a combination of factors that
includes adjusting one’s lifestyle through changes in diet and exercise which, for most
individuals, is an effective way to regulate blood glucose levels. If needed, anti-diabetic
medications are also effective at glycemic control, but which medication is needed must
be evaluated for each T2D individual by identifying which dosage is optimal and through
observing for any side effects or allergies. The age when diagnosed, long-term T2D
diagnosis, and the presence of other health conditions may affect one’s ability to
consistently regulate blood glucose levels and may lead to disease progression resulting
in the development of diabetic complications.
1.2 Impact of Type 2 Diabetes
In about 30% of T1D individuals initially diagnosed and treated with exogenous
insulin, the insulin therapy induces partial clinical remission during the first year in which
improved insulin sensitivity and normoglycemia is observed (Yki-Järvinen & McClain,
2015). In contrast, the common clinical course for T2D individuals is that they initially
respond to therapy and can normalize their fasting blood glucose levels, but there is a
gradual decrease in their glycemic control over time despite management with drugs
which ultimately leads to the development of chronic hyperglycemia (Robertson et al.,
2004). Chronic hyperglycemia induces insulin resistance, which is initially overcome by
hyperinsulinemia, but over time the pancreatic β-cells are unable to respond adequately to

10

the elevated blood glucose levels which leads to glucose toxicity where there is cell
damage to the β-cells and other insulin-sensitive tissues (Giri et al., 2018a; Newsholme et
al., 2019). Over time individuals with T1D may experience chronic hyperglycemia and
insulin resistance through glucose toxicity, but unlike what is observed with T2D
individuals, their insulin sensitivity can be improved, even normalized, through
optimization of their insulin therapy. These differences are important because not only is
the development of T2D different from what is observed with T1D, but there is also a
physiological difference between how T2D is managed through treatment in comparison
to T1D.
The irreversible cell damage seen with glucose toxicity leads to altered insulin
secretion and the impact of glucose toxicity on the pancreatic β-cells and other insulinsensitive tissues is believed to be correlated with the development of various diabetic
complications. Understanding how these factors impact the development of diabetic
complications is the interest of several studies because the major causes of the morbidity
and mortality among T2D individuals is vascular complications (Diabetes. 2021; Giri et
al., 2018b). In T2D individuals where glycemic control is not consistently obtained over
time even through optimal treatment, studies have shown that the β-cell damage observed
with glucose toxicity is due to chronic oxidative stress. With oxidative stress, there is a
decrease or absence in the response of antioxidant mechanisms which leads to the
activation of intracellular stress-associated pathways.
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The oxidation of excess glucose through glycolysis and the Krebs cycle causes an
overproduction of electron donors that burden the electron transport chain (ETC) and
leads to electrons leaking from complex I and III (Giri et al., 2018). These electrons react
with molecular oxygen forming O2- and are converted to H2O2. Because the production of
H2O2 is happening in excess of what would occur under normoglycemic conditions, H2O2
quickly accumulates and is converted to a compound containing a highly reactive
hydroxyl radical. Though pancreatic β-cells possess antioxidant pathways, like catalase
(CAT) and glutathione peroxidase (GPx), to convert H2O2 to H2O and O2, in comparison
to other cells, the β-cells have a lower expression of CAT and GPx which contributes to
an increased susceptibility of the β-cells to damage due to the production of ROS. Studies
also suggest that the oxidative stress in the β-cells during chronic hyperglycemia may be
due to a reduction in the ratio between reduced and oxidized glutathione that contributes
to the reduced antioxidant capability of the pancreatic β-cells (Eguchi et al., 2021).
Chronic hyperglycemia during T2D not only results in oxidative stress in the
pancreatic β-cells, but the vascular tissues are also negatively affected. Studies have
shown that diabetic patients are at a higher risk for developing cardiovascular diseases
and T2D presents adverse physiological conditions that leads to ROS production,
inflammation, and smooth muscle cell proliferation (Giri et al., 2018). The accumulation
of ROS during hyperglycemia has been shown to occur through multiple pathways
including the activation of the protein kinase C (PKC) pathway via diacylglycerol (DAG)
and by an increased activation of the polyol pathway. When glucose is reduced to sorbitol
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via aldose reductase, excess glucose enters the polyol pathway leading to the oxidation of
NADPH to NADP+ (Wang et al., 2021). This causes a reduction in the amount of
NADPH and leads to oxidative stress within the vascular tissues. In addition to the
oxidative stress due to hyperglycemia, studies have also shown that even if diabetes is
well-controlled, there is still some link to the development of pulmonary hypertension
(Grinnan et al., 2016).
1.3 Pulmonary Hypertension
The role of endothelial dysfunction in the pathogenesis of vascular complications
during diabetes has been studied, but there have not been many studies on the role of
vascular smooth muscle dysfunction on the pathogenesis of various vascular
complications during diabetes, especially PH (Nieves-Cintrón et al., 2017). The
pulmonary arteries undergo a process of gas exchange where the deoxygenated blood that
enters the right ventricle of the heart flows to the pulmonary arteries, which branch from
the pulmonary trunk into many smaller arteries and capillaries within the lungs, to be
oxygenated before returning to the left side of the heart (Tucker et al., 2022). Compared
to the arteries in systemic circulation, the pulmonary arteries are thinner due to them
containing less layers of vascular smooth muscle (VSM). The arrangement of the
pulmonary arteries allows for more compliance which, under normal conditions, results
in lower pressure in the pulmonary circulation compared to systemic circulation. Unlike
the rapid contractions and the arrangement that’s seen with striated muscle, vascular
smooth muscle contains an inner circular layer and an outer longitudinal layer of smooth
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muscle which maintains a steady tonic force (Sweeney & Hammers, 2018). Under basal
conditions all arteries experience smooth muscle contraction to some degree which
determines the diameter of the vessel and is known as the myogenic tone. The myogenic
tone, which occurs at a constant physiological blood pressure, plays a role in the
regulation of peripheral vascular resistance, the distribution of blood to the tissues, and
the control of blood pressure (Jackson, 2021). Arteries also exhibit myogenic reactivity
which allows either additional vasoconstriction or vasodilation in response to pressure
changes that allows for autoregulation of blood flow (Natarajan & Koide, 2016a).
PH is a term used to classify elevated pressure in the pulmonary arteries where the
mean pulmonary arterial pressure (mPAP) is greater than 20 mmHg at rest and is due to
structural and functional changes to the pulmonary vasculature (Gelzinis, 2021). Not all
PH has the same cause, therefore the WHO has classified five groups of PH based on the
different causes or comorbidities. Group 1 is caused by pulmonary arterial hypertension
(PAH) where the pulmonary arteries become thickened and stiff, group 2 is caused by left
heart disease which affects how the heart is able to pump blood to the pulmonary arteries
leading to increased mPAP, group 3 is caused by chronic lung disease that causes PH due
to the pulmonary arteries prioritizing blood flow to the areas of the lungs receiving the
most oxygen, group 4 is caused by pulmonary arterial obstruction whenever blood clots
are not dissolved which can lead to scar tissue within the pulmonary arteries, and group 5
is secondary to other diseases and has unknown or multifactorial causes (Gelzinis, 2021;
PHA, ).
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Since studies have shown that diabetic individuals are at risk for systemic
macrovascular and microvascular dysfunction, an emphasis has been placed on
understanding the impact that diabetes has on the development and progression of
vascular complications. Independent of other vascular complications like coronary artery
disease and stroke, studies have shown that individuals with T2D have an increased risk
of developing PH and even with targeted therapies, diabetic patients that develop PH
have worsened long-term survival rates (Abernethy et al., 2015). While the association
between T2D and PH has been identified, the mechanism by which diabetes effects the
pulmonary vasculature leading to the development of PH has not been clearly identified.
The HPASMC express various ion channels which, under normal conditions, play an
important role in the hyperpolarization of these cells and the subsequent vasodilation of
the pulmonary arteries. Though the pathogenesis of PH is unclear, studies have observed
an increased sensitivity of the HPASMC to depolarization which alters the resting
membrane potential in these cells and leads to vasoconstriction in the pulmonary arteries
(Khan et al., 2022). In order to investigate the role of HPASMC dysfunction in the
pathogenesis of secondary PH during T2D, this project specifically evaluates the BKCa
channel and its role in HPASMC dysfunction during T2D.
1.4 BKCa Channels
BKCa channels are large-conductance, voltage-dependent, and calcium-activated
K+ channels and their primary role in HPASMC is to regulate the vascular tone and the
myogenic response through modulation of the cell’s contractility (Natarajan & Koide,
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2016b). These channels are activated by both membrane depolarization and changes to
intracellular Ca2+ concentration (Wu & Marx, 2010). Ca2+ sparks activate these channels
leading to BKCa-mediated spontaneous transient outward currents (STOC) that causes
membrane hyperpolarization leading to the closure of voltage-dependent Ca2+ channels, a
reduction of Ca2+ influx, and vasodilation of the pulmonary arteries.
BKCa channels are the predominate K+ channels found in most arterial smooth
muscle and a functional BKCa channel has an arrangement of 2 different subunits. The αsubunit, encoded by the KCNMA1 gene, has seven helical transmembrane segments
which contain a voltage-sensing domain and forms a cytoplasmic tail with binding sites
for Ca2+ and other regulatory molecules (Krishnamoorthy-Natarajan & Koide, 2016). A
functional BKCa channel pore is formed by a tetramer of α-subunits which contains a
selectivity filter that allows for fast K+ efflux (Carvalho-de-Souza et al., 2012). The β1subunit, encoded by the KCNMB1 gene, is a regulatory protein that functions to enhance
the Ca2+ sensitivity of the BKCa channel and the ratio of α- and β1-subunits is 1:1
(Carvalho-de-Souza et al., 2012; Detweiler et al., 2016). Through the association between
the α- and β1-subunits, the BKCa channel exhibits a greater sensitivity to Ca2+ and
alterations to the channel kinetics allows the channel to remain open for longer periods of
time than what would occur with just the expression of the tetramer of α-subunits alone.
The ability of the BKCa channel to regulate the myogenic tone of vascular smooth
muscle can be modulated through exposure to several different molecules. One of the
primary adjustments to BKCa channel activity is through phosphorylation by protein
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kinase A (PKA), protein kinase C (PKC), and protein kinase G-1 (PKG-1). These protein
kinases are activated by cyclic nucleotides (cAMP and cGMP) that function to positively
regulate BKCa channel activity through an increase in their intracellular HPASMC
concentration. Without affecting the channel’s voltage sensitivity, the actions of PKA and
PKG-1 increases the BKCa channel’s open probability and, through phosphorylation of
phospholamban (a phosphoprotein that inhibits sarcoplasmic (SR) reticulum Ca2+ATPase), it may indirectly increase the channel’s activation by increasing the SR Ca2+
load leading to an increase in the frequency of Ca2+ sparks (Natarajan & Koide, 2016;
Singh & Epstein, 2006). Unlike the actions of PKA and PKG-1 that stimulate BKCa
channel activation, PKC inhibits the BKCa channel through phosphorylation, but this
action appears to be a first step before PKA and PKG-1 are able to phosphorylate the
channel (Barman et al., 2003; Natarajan & Koide, 2016). Overall, the actions of the BKCa
can be altered through phosphorylation to have a stimulatory effect as seen with PKA and
PKG-1 which leads to hyperpolarization of the HPASMC membrane and vasodilation of
the pulmonary arteries, or the channel activity can be altered by an inhibitory action as
seen with PKC which leads to a depolarization of the HPASMC membrane and
vasoconstriction of the pulmonary arteries.
Another molecule that has an effect on the activity of the BKCa channel is nitric
oxide (NO) which is a well-studied vasodilator that is released from vascular endothelial
cells and its actions leads to the relaxation of the HPASMC. The synthesis of NO from Larginine is done by the enzyme NO synthase (NOS) and there are three isoforms of NOS
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that exist: neuronal NOS (nNOS), endothelial (eNOS), and inducible NOS (iNOS). Of
the three isoforms, eNOS has the greatest expression within the pulmonary arteries and it
produces a basal level of NO that adjusts the myogenic tone through smooth muscle cell
relaxation (Natarajan & Koide, 2016). An increase in intracellular Ca2+ concentration
leads to the activation of eNOS which then produces NO that diffuses into the HPASMC.
Once NO is within the HPASMC, it activates the enzyme guanylate cyclase which
synthesizes cGMP. One of the main targets of cGMP within the HPASMC is PKG-1
which, as discussed above, phosphorylates the BKCa channel and increases the channel
activity.
Overall, the BKCa channel plays an important role in the vasodilation of the
pulmonary arteries and its channel activity can be modulated through the actions of
several molecules. Understanding the mechanisms of BKCa channel activity and the
channel’s functional regulation can lead to further understanding of the channel’s role in
the dysfunction of the HPASMC during T2D.
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Aims and Goals
2.1 Previous Research
Previous studies have evaluated the effect of altered BKCa channel functional
regulation during type 2 diabetes on the dysfunction of the HPASMC. The results from
these studies suggest that in the HPASMC from diabetic individuals there is a decreased
association of the BKCa α- and β1-subunits and a decrease in BKCa channel activity
(Nieves-Cintrón et al., 2017). In this study, HPASMC from a non-diabetic individual
(NHPASMC) and HPASMC from a type 2 diabetic individual (D2HPASMC) are used to
further investigate the findings from the previous studies. This project specifically
focuses on identifying the mechanisms by which T2D effects the BKCa channel in the
HPASMC and how impaired functioning of these cells may contribute to the dysfunction
of the pulmonary arteries and the eventual development of PH.
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2.1.1 Preliminary Results of BKCa Channel Expression in Porcine PASMC
Under the guidance of Dr. Shu Zhu, previous students in my lab have used
porcine non-diabetic (normal) and streptozotocin (STZ)-induced type 1 diabetic animal
models for experimentation to evaluate how altered BKCa channel expression may
contribute to the cellular dysfunction observed in the pulmonary arterial smooth muscle
under the diabetic state. The western blot results shown in Figure 1 suggest that there is
some upregulation in the expression of the BKCa channel α-subunit in the diabetic porcine
PASMC. However, there appears to be similar expression of the BKCa channel β1-subunit
in the normal and diabetic porcine PASMC. These results suggest that diabetes presents
adverse conditions that leads to altered expression of the BKCa channel α-subunit.

Figure 1. Western blot results for the BKCa channel subunit expression in normal and
diabetic porcine PASMC. β-actin was used as a loading control.
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2.1.2 Preliminary Results of cAMP Levels in Porcine PASMC
Former animal studies done in my lab involved performing cell-attached patch
clamp experiments to evaluate the impact that impaired BKCa channel functional
regulation plays in dysfunction of the porcine PASMC. As discussed earlier, cAMP leads
to an increase in BKCa channel activity through phosphorylation of the channel by protein
kinases. Through exposure to forskolin, a known adenylate cyclase activator, the
experiment performed in Figure 2 shows the results from a cell-attached patch clamp
experiment using normal porcine PASMC measuring the BKCa channel activity before
and after exposure to forskolin. In comparison to the channel activity prior to forskolin
exposure (control), there is an increase in the open probability of the BKCa channel
following forskolin exposure (forskolin). These results support previous findings on the
ability of cAMP signaling mechanisms to regulate the activity of BKCa channels in the
PASMC.

21

Figure 2. Results from a cell-attached patch clamp experiment evaluating BKCa channel
activity in normal porcine PASMC. A. Continuous recordings from the same cellattached patch (+40 mV). Channel activity at control and 10 min after the application of
10 μM forskolin. Channel openings are upward deflections from baseline (closed state;
dashed line). B. Bar graph of channel open probability under control (0.0053±0.0011)
and after forskolin exposure (0.1186±0.0175).
2.1.3 Preliminary Results of Decreased cAMP Levels in Diabetic Porcine PASMC
cAMP assays were performed using normal and diabetic porcine PASMC and in
Figure 3 the basal cAMP levels (control) and the cAMP levels following exposure to
forskolin (forskolin) are shown. Similar to the results in Figure 2, exposure to forskolin
led to an increase in the cAMP levels in both the normal and diabetic cells. However, in
comparison to the normal porcine PASMC, the diabetic porcine PASMC not only
exhibited lower basal cAMP levels but the forskolin exposure also did not lead to as
much of an increase in the cAMP levels. These results provide further support to the
results from previous studies and to the results shown in Figure 2.
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Figure 3. cAMP levels in the normal and diabetic porcine PASMC. Basal cAMP levels in
diabetic porcine PASMC were lower (~40%) than in normal porcine PASMC, and
forskolin (10μM) increased cAMP generation to a lesser extent in diabetic porcine
PASMC (~10%) compared to normal porcine PASMC.

2.2 Hypothesis
The hypothesis of this project is that altered BKCa channel subunit expression and
functional regulation occurs in the D2HPASMC leading to cellular dysfunction.
2.3 Specific Aim 1
The first aim of my project is to investigate the differences in BKCa channel
subunit expression between NHPASMC and D2HPASMC to evaluate the molecular
differences that T2D poses to the expression of the BKCa channel in HPASMC which
ultimately affects the function of the pulmonary arteries. Through cell cultures, the
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NHPASMC and D2HPASMC will be grown in smooth muscle growth media with
normal glucose (N.G.) and high glucose (H.G.) to mimic normal blood glucose levels and
hyperglycemia in vivo in the NHPASMC and to mimic well controlled T2D exhibiting
normoglycemia and non-controlled T2D exhibiting hyperglycemia in vivo in the
D2HPASMC.
Within the cell growth media, a D-glucose concentration of approximately 5.5
mM is used to estimate normal blood glucose levels in vivo while a D-glucose
concentration close to and above 10 mM D-glucose approximates pre-diabetic and
diabetic blood glucose levels in vivo. The excessive glucose concentration within the
H.G. media has several effects on the HPASMC including an imbalance of the solute
concentrations that leads to the movement of water from the intracellular space of the
cells and also an exposure of the cells to post-translational modifications due to the
excess glucose (Ing et al., 2020; Liman & Jialal, 2022). By growing the NHPASMC and
D2HPASMC under these conditions the differences between the BKCa channel subunit
expression can be evaluated under different physiological states.
Once the cells reach an appropriate cellular confluence cell lysis and protein assay
will be performed then the identification of the BKCa channels in the HPASMC will be
done through western blot analysis to observe the BKCa channel subunit expression
differences between the NHPASMC and D2PASMC in each condition (N.G. and H.G.).
Since the BKCa channels are the predominate K+ channels expressed in vascular smooth
muscle and therefore are important in the vasodilation of the pulmonary arteries, this aim
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evaluates the expression of the BKCa channel in order to provide further understanding of
the relationship between the BKCa channels and the function of the HPASMC.
2.4 Specific Aim 2
In the second aim of this project the differences in cyclic AMP (cAMP) levels
between the NHPASMC and D2HPASMC is investigated to evaluate the impact that
T2D has on the functional regulation of the BKCa channels. Previous studies have shown
that cAMP and cGMP activate the BKCa channels and mediates smooth muscle
vasodilation in the pulmonary arteries (Barman et al., 2003). As nitric oxide (NO) is
released from the endothelial cells of the pulmonary arteries, it acts on guanylate cyclase
in the smooth muscle cells which then catalyzes cGMP from GTP. Cyclic GMP then
activates protein kinase G (PKG) that then phosphorylates the α-subunit of the BKCa
channel thus activating the channel. Similar actions are observed cAMP activates protein
kinase A which phosphorylates the BKCa channel α-subunit to activate the channel.
Through exposure to a known adenylate cyclase activator, the differences in cAMP levels
in the NHPASMC and D2HPASMC will be measured using assays to provide further
evidence of the role that this cyclic nucleotide may play in the vasodilation of the
pulmonary arteries through BKCa channel activation.
2.5 Significance
The goal of this research is to identify and analyze the differences in BKCa
channel expression and functional regulation in NHPASMC and D2HPASMC. By doing
this, further understanding of the properties of BKCa channels in HPASMC can be
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achieved which may lead to identifying factors that could contribute to the development
of pulmonary hypertension in type 2 diabetic individuals.
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Methods
3.1 Cell Cultures
Human pulmonary artery smooth muscle cells (Lonza) were used for
experimentation. Cells were from a non-diabetic 58-year-old female donor (NHPASMC)
and a type 2 diabetic 63-year-old female donor (D2HPASMC). The cells were grown in
two separate 25 cm2 polystyrene cell culture flasks with 7 mL of smooth muscle basal
growth medium (SmBM-2, Lonza) supplemented with the smooth muscle cell growth
medium SingleQuots kit (Lonza) and 1% penicillin/streptomycin under optimal
incubation conditions (37 °C and 5% CO2). The cell media was changed every 48 hours
in order to maintain optimal cell growth conditions until cellular confluence reached
~90%. Next, subculturing was done by first removing the cell media and replacing it with
1 mL of 0.25% trypsin/EDTA to detach the cells from the surface of the cell culture flask.
After about 5 minutes, 4 mL of cell media was added to the flask then all the contents of
the flask were transferred to a 50 mL tube and centrifuged at 1,000 rpm for 10 minutes.
After centrifugation, the supernatant was removed, and the cells were resuspended using
fresh cell media then transferred to new cell culture flasks and allowed to grow under
incubation.
Upon the third passage (P) of cells, subculturing was done to produce three
separate cell culture groups for both the NHPASMC and D2HPASMC. After trypsination
and centrifugation, the cells were resuspended and equally distributed into one 25 cm2
polystyrene cell culture flask and two 60 mm polystyrene cell culture plates. The cells in
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the cell culture flask and one of the cell culture plates were grown in the smooth muscle
basal growth medium described above, which contains a normal glucose concentration
(N.G.). The other cell culture plate was grown in Gibco™’s DMEM, high glucose (H.G.)
medium supplemented with 5% fetal bovine serum (FBS). The cells were again allowed
to grow under optimal incubation conditions with fresh media being replaced every 48
hours until cellular confluence reached ~90%. This process was repeated until P9.
3.2 Cell Lysis and Bicinchoninic Acid (BCA) Protein Assay
The NHPASMC and D2HPASMC cell culture plates grown in N.G. and H.G.
media were placed on ice once the cellular confluence reached ~90%. The media was
removed, and each plate was washed with 1 mL of 1X phosphate buffered saline (PBS).
After the PBS was removed, 60 µL of lysis buffer was added to each plate. A sterile cell
scraper was used to detach the cells in the lysis solution and the cell lysates were pipetted
into 1.5 mL microcentrifuge tubes. Next, the cell lysates were centrifuged at 13.3 min-1
for 10 minutes at 4°C and the supernatant was then transferred to new 1.5 mL
microcentrifuge tubes. Next, a Pierce™ bicinchoninic acid (BCA) protein assay kit
(ThermoFisher Scientific) was used following the manufacturer’s instructions to
determine the protein concentration of the supernatant from each sample. The samples
were frozen at -20°C until further experimentation.
3.3 Western Blot Analysis
The samples containing the cell lysates’ supernatant from the BCA protein assay
described above were placed on ice and allowed to thaw. New 1.5 mL microcentrifuge
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tubes containing the samples were made using the protein concentration determined by
the BCA protein assay so that when the samples were loaded to each well of the gel, they
contained a constant protein mass. To those samples, 4X loading buffer was added and
the tubes were heated in boiling water for 10 minutes. Next, using either a 10% or 15%
polyacrylamide gel, which was made following the protocol by E. Harlow and D. Lane,
the samples were added to the wells of the gel (Wright, 1989). Gel electrophoresis was
performed at 60 mV and once the samples passed the stacking portion of the gel, voltage
was raised to 100 mV. Once the samples reached the bottom of the gel, electrophoresis
was ceased. Polyvinylidene fluoride (PVDF) membranes were briefly placed in 100%
ethanol to wet the membranes then the membranes and membrane stacks were placed in
transfer buffer. The membrane and gel were stacked then placed in the cassette of the
Trans-Blot Turbo Transfer System (Bio-Rad) and run at 25 volts for 14 minutes.
Next, the PVDF membranes were placed in blocking buffer solution (Li-COR)
and were allowed to rock gently overnight in a 4°C refrigerator. The next day, the
blocking buffer solution was removed, and the membranes were stained with a rabbit
primary antibody against the BKCa channel α-subunit (1:500, Alomone labs) mixed in
blocking buffer solution with 0.1% Tween20 for 1 hour at room temperature while gently
rocking. Afterwards, the solution was removed, and the membranes were washed 4 times
with PBS + 0.1% Tween20 (PBST) for 5 minutes while gently rocking. The membranes
were then stained with an anti-rabbit secondary antibody against the BKCa channel α-
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subunit (1:5000, Alomone labs) mixed in blocking buffer with 0.1% Tween20 solution
for 1 hour at room temperature while gently rocking.
Next, the membranes were washed again with PBST 4 times for 5 minutes while
rocking and similar steps as done to stain the membranes against the BK channel αsubunit were taken to stain the membranes with a mouse primary antibody (1:5000) and
anti-mouse secondary antibody (1:5000) against β-actin. After membrane washing with
PBST, the membranes were stained with the rabbit primary antibody (1:5000; Genetex)
then the anti-rabbit secondary antibody (1:5000; Alomone labs) against the BKCa channel
β1-subunit following the same steps that were used to stain against the BK channel αsubunit. Lastly, the membranes were washed twice with PBS for 5 minutes while gently
rocking at room temperature then the membranes were imaged using the LI-COR
Odyssey machine.
3.4 Cyclic AMP Assay
Starting with similar steps that were done with the cell cultures described above, upon
subculturing of the third passage of NHPASMC and the D2HPASMC cell culture flasks,
three separate cell culture groups were started for both the NHPASMC and D2HPASMC:
a cell culture flask with N.G. media, a cell culture plate with N.G. media, and a cell
culture plate with H.G. media. Once the N.G. and H.G. cell culture plates for both the
NHPASMC and D2HPASMC reached ~90% confluence, trypsinization and
centrifugation was done then the cells grown in the N.G. and H.G. media were
resuspended in their respective media then each was distributed to an individual 6-well
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plate. The cells were equally distributed to three of the six wells with 2 mL of the
respective media added to each well. The cells were allowed to grow under optimal
incubation conditions with fresh media being replaced every 48 hours until cellular
confluence reached ~90%. This process was repeated until P9.
Once the cells reached ~90% cellular confluence, the media was removed from each
well and replaced with the respective low serum media (1%) then incubated for 18 hours.
Following incubation, the cells were washed three times with a wash buffer (1 mL/well)
that contained 0.1% FBS. Next, the cells were preincubated for 15 minutes with 2 mL of
their respective media that contained 0.1 mM 3-isobutyl-1-methylxanthine (IBMx) to
inhibit the phosphodiesterase activity. Afterwards, 0.1 mM Forskolin was added to one of
the wells and another well was treated with an equivalent amount of the vehicle (100%
ethanol) then the plate was incubated again for 10 minutes. Following incubation, the
media was removed from each well then 0.5 mL of 0.1 M HCl was added to each well
and allowed to rock gently for 30 minutes at room temperature. The cAMP levels were
then determined using a Cyclic AMP Competitive ELISA kit (ThermoFisher Scientific)
and by following the manufacturer’s instructions.
3.5 Statistical Analysis
All data is expressed as means ± SE. Statistical significance between two groups
is evaluated by t-test for paired data. Comparison among multiple groups is made by
using one-way ANOVA for multiple comparisons. A p-value < 0.05 is considered to
indicate a significant difference.
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Results
4.1 Altered BKCa Channel Expression in the D2HPASMC
4.1.1 BKCa Channel α-subunit Expression
Figure 4 is the western blot results for the expression of the BKCa channel αsubunit in the NHPASMC and D2HPASMC grown in N.G. and H.G. media. Although
these results do not follow the exact trend seen in the preliminary results from the porcine
PASMC (Figure 1), it still provides some insight into the impact of type 2 diabetes on
BKCa channel α-subunit expression in the HPASMC.

Figure 4. Western blot results of BKCa channel α-subunit expression in NHPASMC and
D2HPASMC (N.G. and H.G. conditions) in comparison to the expression of β-actin
The BKCa channel α-subunit expression in the NHPASMC and D2HPASMC was
normalized against the loading control, β-actin. The results are shown in Figure 5 and
were calculated using the data from 3 different western blot experiments with 3 groups of
samples in each. Overall, there were no significant differences in the normalized densities
from the expression of the BKCa channel α-subunit in the D2HPASMC in comparison to
the NHPASMC, but an increase in expression is observed in the H.G. condition of each
cell group. There was a nearly 0.16-fold increase in the NHPASMC (H.G.) when
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compared to the NHPASMC while there was about a 0.51-fold increase in the
D2HPASMC (H.G.) compared to the D2HPASMC (N.G.).

β-actin normalized densitometric units
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Figure 5. Normalized western blot data for the BKCa channel α-subunit expression in the
NHPASMC and D2HPASMC (N.G. and H.G. conditions)
4.1.2 BKCa Channel β1-subunit Expression
The western blot experiment in Figure 6 shows the expression of the BKCa
channel β1-subunit in comparison to the expression of β-actin in the NHPASMC and
D2HPASMC. Unlike the preliminary results (Figure 1.), there is not a clear consistency
in the expression of the BKCa channel β1-subunit in the NHPASMC and D2HPASMC.

Figure 6. Western blot results of BKCa channel β1-subunit expression in NHPASMC and
D2HPASMC (N.G. and H.G. conditions)
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The data for the BKCa channel β1-subunit expression were normalized against βactin and the results are shown in Figure 7. These results were calculated using the data
from 2 western blot experiments, one with 3 groups of samples and one with 2 groups of
samples. There were not any significant differences in the expression of the β1-subunit in
the D2HPASMC in comparison to the NHPASMC, but the D2HPASMC (N.G.)
increased by over 2-fold compared to the NHPASMC (N.G.).
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Figure 7. Normalized western blot data for the BKCa channel β1-subunit expression in the
NHPASMC and D2HPASMC (N.G. and H.G. conditions)
4.2 Decreased cAMP Levels in the D2HPASMC
The results from a cyclic AMP competitive ELISA are shown in Figure 8.
Compared to the basal cAMP levels (control), an increase in cAMP levels was observed
in all samples following forskolin exposure (forskolin). However, in the NHPASMC and
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D2HPASMC samples grown in H.G. media, forskolin exposure did not elicit as much of
an increase in cAMP level as seen in the samples grown in N.G. media. The basal cAMP
levels in the NHPASMC (N.G.) was 232.758 pg/mL while the basal cAMP levels in the
NHPASMC (H.G.) was 0.0583 pg/mL. Following exposure to forskolin, the NHPASMC
(N.G.) had a cAMP concentration of 252.986 pg/mL and the NHPASMC (H.G.) only had
a cAMP concentration of 6.203 pg/mL. While a similar trend was observed with the
D2HPASMC, the cAMP levels were overall lower than those recorded in the
NHPASMC. The basal cAMP levels in the D2HPASMC (N.G.) was 129.887 pg/mL
while the basal cAMP levels in the D2HPASMC (H.G.) was 0.0.0141 pg/mL. Following
exposure to forskolin, the concentration of cAMP within the D2HPASMC (N.G.) was
223.259 pg/mL while the D2HPASMC (H.G.) only had a cAMP concentration of 16.173
pg/mL.

35

Figure 8. A summary of all the results from the cyclic AMP competitive ELISA
A side-by-side comparison of the cAMP levels in the different cell groups is
shown in Figure 9. In Panel A, the differences in cAMP levels between the NHPASMC
and D2HPASMC can be seen. In the NHPASMC, forskolin exposure resulted in an
increase in cAMP levels when compared to the basal (control) cAMP levels (0.08-fold in
the N.G. and 0.02-fold in the H.G.). When comparing the samples from the N.G. and
H.G. conditions, the samples from the H.G. condition have decreased cAMP levels not
only at the basal state but also after forskolin exposure. When comparing the
D2HPASMC to the NHPASMC, the D2HPASMC (N.G.) sample have overall lower
cAMP levels while the D2HPASMC (H.G.) sample show slightly higher cAMP levels. In
both cell groups, the samples from the H.G. conditions had very low cAMP levels and
exposure to forskolin did not cause the expected increase in cAMP levels as observed in
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the samples from the N.G. conditions. In comparison to the NHPASMC (N.G.), the
D2HPASMC (N.G.) sample had overall lower cAMP levels even following forskolin
exposure (Panel B). In Panel C the cAMP levels in both cell groups are lower than those
seen in Panel B, with the basal cAMP levels in the D2HPASMC (H.G.) being lower than
the NHPASMC (H.G.) while the cAMP levels are slightly higher in the D2HPASMC
(H.G.) following forskolin exposure. This suggests a trend of decreased cAMP levels in
the D2HPASMC and in the cell samples grown in hyperglycemic conditions.
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Figure 9. Panel A. A comparison of cAMP levels between the NHPASMC and
D2HPASMC (N.G. and H.G. conditions). Panel B. A comparison of the cAMP levels
between the N.G. conditions of the NHPASMC and D2HPASMC. Panel C. A
comparison of the cAMP levels between the H.G. conditions of the NHPASMC and
D2HPASMC
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Discussion
As discussed earlier, type 2 diabetes has serious systemic effects that impact the
body’s ability to utilize insulin leading to chronic hyperglycemia and the progressive
effects of the disease can ultimately lead to the development of pulmonary hypertension.
HPASMC play a vital role in maintaining vascular tone and exhibiting myogenic
reactivity in pulmonary arteries through the ability of the BKCa channel to regulate
pulmonary arterial pressure. Previous studies have evaluated the role that altered BKCa
channel expression and function plays in the dysfunction of the HPASMC during type 2
diabetes. This dysfunction ultimately leads to adverse conditions that may contribute to
the development of pulmonary hypertension. The results from those studies greatly
influenced the hypothesis and aims of this thesis project. This discussion evaluates the
results from other studies and those found in this project in order to provide a thorough
analysis of the hypothesis, the techniques employed, and predictions for how this
research can move forward in the future.
Nieves-Cintrón et al. (2017) used small diameter adipose arteries to demonstrate
impaired BKCa channel function in HPASMC from type 2 diabetic patients which was
evidenced through a reduction in the BKCa channel’s Ca2+ sensitivity and through a
reduction in the association between the α- and β1-subunits. These alterations to the BKCa
channel’s activity have serious impacts on the myogenic reactivity of the HPASMC in
the arteries and provide evidence that, independent of the impact that has been previously
shown with endothelial dysfunction, impaired BKCa channel function in type 2 diabetic
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patients may contribute to the development of vascular complications. Morales-Cano et
al. (2019) demonstrated the link between type 2 diabetes and the risk of developing PH
by using Zucker diabetic fatty rats (ZDF), a clinically relevant model of type 2 diabetes,
and measuring the differences between the systolic, diastolic, and mean pulmonary
arterial pressures in comparison to the values observed in the obese non-diabetic Zucker
model (OZR) (Morales-Cano et al., 2019). The ZDF, in comparison to the OZR,
exhibited significantly elevated systolic, diastolic, and mean pulmonary arterial pressures.
Additionally, by measuring the Fulton Index (calculated by right ventricle weight/left
ventricle and septum weight) right ventricular hypertrophy, which often results from PH,
was shown to be correlated with the increased mean pulmonary arterial pressures. These
results provide support to previous findings that type 2 diabetes increases the risk for
developing PH.
Some preliminary results from our lab suggests that there is an increase in the
expression of the BKCa channel α-subunit in the diabetic porcine PASMC in comparison
to the normal porcine PASMC (Figure 1). In this project, there was an increase in the
expression of the BKCa channel α-subunit in the H.G. condition of each cell group
compared to the N.G. condition, and the D2HPASMC overall had a higher expression of
the α-subunit than the NHPASMC (Figure 5). Though this trend was observed, statistical
analysis showed that there were no significant differences in the expression of the BKCa
channel α-subunit in the D2HPASMC in comparison to the NHPASMC in either the N.G.
or H.G. conditions. These results suggest that the HPASMC grown under hyperglycemic
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conditions and the cells from type 2 diabetic patients may increase the expression of the
BKCa channel α-subunit in an attempt to overcome the negative effects presented by the
diseased state and/or the hyperglycemic extracellular environment.
In addition, there was an increase in the expression of the BKCa channel β1subunit in the NHPASMC grown under H.G. conditions in comparison to the NHPASMC
grown under N.G. conditions (Figure 7). While the opposite was observed with the
D2HPASMC, with there being a decrease in expression of the β1-subunit in the cells
grown in H.G. conditions compared to the cells grown in N.G. conditions (Figure 7). This
suggests that the NHPASMC grown under H.G. conditions may try to compensate for
any impaired BKCa channel activity by increasing the expression of the β1-subunit.
Whereas the D2HPASMC attempt to increase the expression of the β1-subunit to
compensate for the effects of the disease, but in the cells grown in the H.G. conditions
there is likely a decrease in expression because of the inability of the cells to overcome
the impact that the hyperglycemic environment has on the BKCa channel expression and
activity. Since the BKCa channel β1-subunit functions to regulate the Ca2+ sensitivity of
the channel, which is crucial to the channel’s activity, the altered expression that is shown
suggests that the cells undergo changes on the molecular level to adjust the expression of
the β1-subunit depending on the needs of the cell. While the cells attempt to overcome
the effects of the diseased state and/or hyperglycemic conditions, the impact that these
conditions have on the cell may lead to improper channel activation due to the
altered/decreased β1-subunit expression.
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Prior studies on the role of vascular smooth muscle dysfunction in the
development of PH during T2D provided a basis for this thesis project which focused on
evaluating the functional regulation of the BKCa channel in the D2HPASMC. The
structure and function of the pulmonary arteries allows for a low-pressure system which,
under normal conditions, allows for the pulmonary arterial diameter to be adjusted
through the activity of modulatory molecules that either lead to relaxation or constriction
of the arteries based on the pulmonary pressure that needs to be achieved. More
specifically, cyclic nucleotides (cAMP and cGMP) have signal transduction mechanisms
that regulate the vascular tone within the pulmonary arteries through actions that directly
impact the function of the BKCa channels in the HPASMC. It is believed that cAMP leads
to vascular relaxation through some involvement with PKA activation, but the exact
mechanism is unclear. Similarly, cGMP has also been identified to stimulate vasodilation
through activating PKG. There have also been some studies that suggest cAMP
stimulating agents may not only lead to vasodilation through PKA activation, but it may
also lead to PKG activation too.
Barman et al. (2003) used the fawn-hooded rat (FHR), a known animal model of
pulmonary hypertension, to demonstrate the effect of cAMP on BKCa channel activity
through the use of cAMP-elevating agents. Using patch clamp experiments, the BKCa
channels in the PASMC were activated via cAMP-dependent vasodilators independent of
PKA activation. After exposure to forskolin and CPT-cAMP, a membrane-permeable
derivative of cAMP, patch clamp recordings indicated increased BKCa channel activity.
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Then following exposure to tetraethylammonium, a selective BKCa channel inhibitor,
patch clamp recordings indicated inhibition to the BKCa channels. After exposure to
KT5720, a PKA inhibitor, there were no changes to the BKCa channel activity that was
observed following forskolin or CPT-cAMP exposure. In separate patch clamp
experiments, cell-attached patches were first exposed to either forskolin or CPT-cAMP
and allowed to record channel activity for 10 minutes which resulted in an increase in
BKCa channel activity. KT5823, a PKG inhibitor, was then added to the cell-attached
patches for 30 minutes which resulted in inhibition in the BKCa channel activity. These
results suggest cAMP-elevating agents activate the BKCa channels in the FHR in a PKAindependent and PKG-dependent manner, which provide support to the studies that
suggest in pulmonary arterial smooth muscle, there is cross-activation of protein kinases
via different cyclic nucleotides. The results from this and other studies provide evidence
that the function of the BKCa channel can be modulated via different vasodilatory
molecules to increase the channel’s activity. In this project, cyclic AMP assays were done
on D2HPASMC and NHPASMC to evaluate the previous findings from animal studies
on the effect of cAMP-dependent vasodilators on BKCa channel activity.
In the previous studies from our lab, results from cAMP assays show the
stimulatory effect of forskolin on the cAMP concentration within the porcine PASMC
(Figure 3). Our results showed a similar trend where forskolin exposure led to an increase
in cAMP levels across all cell groups providing support to previous findings on the
vasodilatory effect of cAMP on the pulmonary arteries via BKCa channel activation
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(Figure 8). In Figure 3, the diabetic porcine PASMC have lower cAMP levels compared
to the normal porcine PASMC. In our results, the D2HPASMC had overall lower cAMP
levels than the NHPASMC which may be due to the impact that T2D has on cAMP’s
ability to increase BKCa channel activity (Figure 9). This impact is likely due to
molecular changes that occur from the irreversible damage that T2D has on these cells
leading to altered function in the cAMP signaling mechanisms that modulate the BKCa
channel activity. Our results also showed that the cells grown in H.G. media had lower
cAMP levels than the cells grown in N.G. media, even after forskolin exposure (Figure
9). This trend suggest that hyperglycemic conditions also have an impact on cAMP
signaling mechanisms leading to decreased BKCa channel activity. Further studies must
be done in order to understand whether cAMP effects BKCa channel activity in the
D2HPASMC and the H.G. cell groups in a PKA-independent and/or PKG-dependent
manner as seen in Barman et al. (2003) and to identify how these mechanisms are
impacted by T2D.
Though this thesis project yielded results, time limited our ability to perform
additional experiments. Future research should focus on more western blot experiments
for further analysis of the BKCa channel subunit expression in the D2HPASMC to clearly
define how expression of the channel’s subunits are likely altered due to type 2 diabetes’s
impact to the channel on the molecular level. While the cAMP assays provided some
results, further experiments should be done using additional cAMP-elevating and
inhibitory agents to evaluate the mechanisms in which cAMP modulates BKCa channel
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activity and how it is impacted by type 2 diabetes. In addition to cAMP assays, cGMP
assays should be done to test how the signaling mechanisms may be affected by type 2
diabetes through evaluating how different cGMP-elevating and inhibitory agents alters
the cGMP levels in the D2HPASMC. This further experimentation may lead to
understanding the mechanisms that type 2 diabetes impairs in the HPASMC via the BKCa
channel that may lead to the eventual development of PH.
In conclusion, by using a human cell model this thesis project provided a novel
approach to evaluating the impact of T2D on the function of the pulmonary arteries. The
findings from the cAMP assay provides evidence of cAMP’s role in regulating the
vascular tone of the pulmonary arteries through BKCa channel activation and suggest a
decrease in cAMP levels in the D2HPASMC which further supports evidence of how
type 2 diabetes impairs the function of the BKCa channel. Overall, this project provided
insight into the impact that type 2 diabetes has on the pulmonary artery smooth muscle
cells leading to cellular dysfunction via altered expression and function of the BKCa
channel which may be a key target for the development of pulmonary hypertension.
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